Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report by Li Shen, Haiyan Chen, Qichun Wei

“…In this manuscript, we presented a patient with metastatic thymoma administrated of anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab. …”
Get full text

Systemic Therapy for Microsatellite Instability Small Bowel Adenocarcinoma With Mesenteric Vascular Embolism as Initial Symptom: A Case Report by Zhongyi Dong, Xiang Xia, Zizhen Zhang

“…Here, we report a rare small bowel adenocarcinoma case with mesenteric vascular embolization and microsatellite instability, in which palliative surgery combined with chemotherapy and anti-Programmed cell death protein 1(PD-1) therapy resulted in complete remission.Case Presentation: The patient was a 55-year-old man who was admitted for suspected small bowel adenocarcinoma combined with incomplete ileus, mesenteric vascular occlusion and distant metastasis. …”
Get full text

Research progress in immune checkpoint inhibitors for lung cancer in China by Jiadi Gan, Yihua Huang, Wenfeng Fang, Li Zhang

“…Among these, four imported programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have received approval for six indications, and one domestic PD-1 inhibitor has received approval for one indication for lung cancer in 2018. …”
Get full text

PD-1 Blockade-Induced Hemophagocytic Lymphohistiocytosis, a Dilemma Therapeutic Outcome in 2 Patients with CAEBV: A Case Series by Chen L, Wang J, Wang Z

“…Herein, we first report 2 cases of patients with chronic active Epstein-Barr virus infection (CAEBV) who developed HLH after the use of sintilimab, a monoclonal antibody against programmed cell death protein 1 (PD-1), and the DEP (liposomal doxorubicin, etoposide, methylprednisolone) chemotherapy regimen in combination with ruxolitinib were used to successfully control the disease.Keywords: PD-1 blockade, hemophagocytic lymphohistiocytosis, CAEBV, case report case series…”
Get full text

Mismatch Repair Deficiency and Microsatellite Instability by Sandra Schöniger, Josef Rüschoff

“…MMRd and MSI predispose to tumor initiation and progression, increase tumor mutational burden as well as tumor immunogenicity, facilitate the activation of the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint pathway and serve as prognostic and predictive biomarkers in solid tumors.…”
Get full text

Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis by Leilei Fang, Changqin Liu, Xiaomin Sun, Zhanju Liu

“…Immune checkpoint inhibitor (ICI)-induced colitis is one of the known complications of therapies targeting cytotoxic programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and programmed cell death ligand 1 (PD-L1). …”
Get full text

Dostarlimab: From preclinical investigation to drug approval and future directions by Carlo Maria Cicala, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso

“…One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-cell death protein 1 and its ligand, overexpressed in several tumor types. …”
Get full text

Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection by Michael Flynn, Lisa Pickering, James Larkin, Samra Turajlic

“…Immune-checkpoint inhibitors (ICPIs), including antibodies against cytotoxic T-lymphocyte associated antigen 4 and programmed cell death protein 1, have been shown to induce durable complete responses in a proportion of patients in the first-line and refractory setting in advanced melanoma and renal cell carcinoma. …”
Get full text

Are radiologists ready to evaluate true response to immunotherapy? by Inci Kizildag Yirgin, Sukru Mehmet Erturk, Izzet Dogan, Sezai Vatansever

“…Immunotherapy, using immune checkpoint inhibitors (ICIs), including drugs targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 or its ligand, promise a new role that has demonstrated improvement management in cancers resistant to chemotherapy. …”
Get full text

Primary central nervous system Hodgkin's lymphoma: a case report by Haiying Fu, Songsheng Shi, Lusan Chen, Benhua Xu, Wanling Huang, Yi Chen, Xuejing Wu, Jianzhen Shen, Tingbo Liu

“…The patient was treated with 3 g/m 2 methotrexate (intravenous [i.v.], once a day, day 1) and 1 g/m 2 cytarabine (i.v., every 12 h, days 2 + 3), followed by anti-programmed cell death protein 1 antibodies (200 mg sintilimab, i.v., once a day, day 1, every 3 weeks). …”
Get full text

The Role of Immune Checkpoint Inhibitors in Cancer Therapy by Ahmed M. Basudan

“…Pointedly, three immune checkpoint molecules have been under extensive research, which include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) and its ligand-1 (PD-L1). …”
Get full text

The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review by Barbara Seliger

“…Different monoclonal antibodies directed against immune checkpoints, e.g., the T lymphocyte antigen 4 and the programmed cell death protein 1/ programmed cell death ligand 1 have been successfully implemented for the treatment of cancer. …”
Get full text

Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. by Yun Wang, Kelvin Zhang, Peter Georgiev, Steven Wells, Haiyan Xu, Brian M Lacey, Zangwei Xu, Jason Laskey, Robbie Mcleod, Joey L Methot, Mark Bittinger, Alexander Pasternak, Sheila Ranganath

“…Moreover, the combination of Compound 1 with pembrolizumab, a humanized monoclonal antibody against the programmed cell death protein 1 (PD-1), demonstrated a synergistic effect, resulting in enhanced interferon (IFN)-γ production. …”
Get full text

Anti-Tumor Potential of Post-Translational Modifications of PD-1 by Xiaoming Xi, Wuli Zhao

“…Programmed cell death protein-1 (PD-1) is a vital immune checkpoint molecule. …”
Get full text

PD-1/PD-L1 axis in organ fibrosis by Youliang Zhao, Yaqian Qu, Changfu Hao, Wu Yao

“…Immune checkpoint molecules are key regulators to maintain immune tolerance and homeostasis, among which the programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) axis has attracted much attention. …”
Get full text

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway by Momtaz P, Postow MA

“…Keyword: immune checkpoints, immunotherapy, programmed cell death protein-1, cytotoxic T-lymphocyte antigen 4…”
Get full text

Current insight into the regulation of PD-L1 in cancer by Zhuandi Liu, Xibao Yu, Ling Xu, Yangqiu Li, Chengwu Zeng

“…Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1, CD274) immune checkpoint. …”
Get full text

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers by Yuji Eso, Hiroshi Seno

“…The development of immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death protein ligand 1 (PD-L1) has revolutionized the treatment strategy in various types of cancers. …”
Get full text

Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma by Jiajia Du, Xing Lv, Zunyi Zhang, Zhiyong Huang, Erlei Zhang

“…There is ongoing research on programmed cell death protein 1 inhibitors (PD-1), chimeric antigen receptor T cells (CAR-T) and tumor-infiltrating leukocyte (TILs). …”
Get full text

Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer by Shuang ZHANG, Jingjing LIU, Ying CHENG

“…In recent years Tumor immunotherapy has shown promising efficacy, especially in immune checkpoints including inhibitors programmed cell-death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). …”
Get full text